NCT03030300

Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 170 (actual)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 78 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.

Conditions

• Type2 Diabetes

Interventions

Type	Name	Description
DRUG	Novolin 30R;Pioglitazone;Metformin	* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued; * Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin; * Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone.

Timeline

• Start date: 2008-01-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2017-01-25
• Last updated: 2017-01-25

Locations

3 sites across 1 country: China